According to the company, this innovative new system is designed to enhance cervical cancer screening for cytology laboratories using the BD SurePath Pap test slides to detect evidence of squamous carcinoma, adenocarcinoma and their usual precursor conditions.
Vincent Forlenza, executive vice president of BD, said: “The launch of the BD FocalPoint GS System represents a key milestone in our effort to expand BD’s presence in cancer diagnostics.
“It is the first in a series of innovative products aimed at improving the detection and clinical management of cancer, resulting from our TriPath acquisition.”